BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8976765)

  • 1. Evaluation of local immune response after intravesical bacille Calmette-Guérin treatment for superficial bladder cancer.
    Patard JJ; Muscatelli-Groux B; Saint F; Popov Z; Maille P; Abbou C; Chopin D
    Br J Urol; 1996 Nov; 78(5):709-14. PubMed ID: 8976765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.
    De Boer EC; De Jong WH; Steerenberg PA; Aarden LA; Tetteroo E; De Groot ER; Van der Meijden AP; Vegt PD; Debruyne FM; Ruitenberg EJ
    Cancer Immunol Immunother; 1992; 34(5):306-12. PubMed ID: 1540977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical evans BCG therapy.
    Jackson AM; Prescott S; Hawkyard SJ; James K; Chisholm G
    Cancer Immunol Immunother; 1993; 36(1):25-30. PubMed ID: 8093683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin.
    De Boer EC; De Jong WH; Van Der Meijden AP; Steerenberg PA; Witjes JA; Vegt PD; Debruyne FM; Ruitenberg EJ
    Cancer Immunol Immunother; 1991; 33(6):411-6. PubMed ID: 1878894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of cellular tumour rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guérin treatment.
    Saint F; Patard JJ; Groux Muscatelli B; Lefrere Belda MA; Gil Diez de Medina S; Abbou CC; Chopin DK
    BJU Int; 2001 Oct; 88(6):602-10. PubMed ID: 11678759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic immune response after intravesical instillation of bacille Calmette-Guérin (BCG) for superficial bladder cancer.
    Taniguchi K; Koga S; Nishikido M; Yamashita S; Sakuragi T; Kanetake H; Saito Y
    Clin Exp Immunol; 1999 Jan; 115(1):131-5. PubMed ID: 9933432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10.
    Poppas DP; Pavlovich CP; Folkman J; Voest EE; Chen X; Luster AD; O'Donnell MA
    Urology; 1998 Aug; 52(2):268-75; discussion 275-6. PubMed ID: 9697793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy.
    Jackson AM; Alexandroff AB; Kelly RW; Skibinska A; Esuvaranathan K; Prescott S; Chisholm GD; James K
    Clin Exp Immunol; 1995 Mar; 99(3):369-75. PubMed ID: 7882559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review.
    Patard JJ; Saint F; Velotti F; Abbou CC; Chopin DK
    Urol Res; 1998; 26(3):155-9. PubMed ID: 9694595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Assessment of 8-hydroxy-2'-deoxyguanosine concentrations in bladder cancer patients treated with intravesical BCG instillation].
    Kaczmarek P; Błaszczyk J; Fijałkowski P; Sierakowska-Fijałek A; Niemirowicz J; Kasprzak A; Baj Z
    Pol Merkur Lekarski; 2005 Oct; 19(112):526-8. PubMed ID: 16379317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
    Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
    J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
    Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
    Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer.
    Saint F; Patard JJ; Maille P; Soyeux P; Hoznek A; Salomon L; Abbou CC; Chopin DK
    J Urol; 2002 Jan; 167(1):364-7. PubMed ID: 11743357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What are the immunologically active components of bacille Calmette-Guérin in therapy of superficial bladder cancer?
    Zlotta AR; Van Vooren JP; Denis O; Drowart A; Daffé M; Lefèvre P; Schandene L; De Cock M; De Bruyn J; Vandenbussche P; Jurion F; Palfliet K; Simon J; Schulman CC; Content J; Huygen K
    Int J Cancer; 2000 Sep; 87(6):844-52. PubMed ID: 10956396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin.
    van der Meijden AP; Steerenberg PA; van Hoogstraaten IM; Kerckhaert JA; Schreinemachers LM; Harthoorn-Lasthuizen EJ; Hagenaars AM; de Jong WH; Debruijne FM; Ruitenberg EJ
    Cancer Immunol Immunother; 1989; 28(4):287-95. PubMed ID: 2784716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local immune response after intravesical interferon gamma in superficial bladder cancer.
    Stavropoulos NE; Ioachim E; Pavlidis N; Pappa L; Kalomiris P; Agnantis NJ
    Br J Urol; 1998 Jun; 81(6):875-9. PubMed ID: 9666774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy.
    Prescott S; James K; Hargreave TB; Chisholm GD; Smyth JF
    J Urol; 1990 Nov; 144(5):1248-51. PubMed ID: 2122008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.